SEARCH

SEARCH BY CITATION

References

  • 1
    Flegal, K. M., Carroll, M. D., Kuczmarski, R. J., Johnson, C. L. (1998) Overweight and obesity in the Unites States: prevalence and trends, 1960–1994. Int J Obes 22: 3947.
  • 2
    Björntorp, P. (1997) Obesity. Lancet 350: 423426.
  • 3
    Manson, J. E., Willett, W. C., Stampfer, M. J., et al (1995) Body weight and mortality among women. N Engl J Med 333: 677685.
  • 4
    McGinnis, J. M., Toege, W. H. (1993) Actual causes of death in the United States. JAMA 270: 22072212.
  • 5
    van Gaal, L. F., Wauters, M. A., de Leeuw, IH. (1997) The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes 21 (Suppl. 1): S59.
  • 6
    Goldstein, D. I. (1992) Beneficial health effects of modest weight loss. Int J Obes 16: 397415.
  • 7
    Hyman, F. N., Sempos, E., Saltsman, J., Glinsmann, W. H. (1993) Evidence for success of caloric restriction in weight loss and control: summary of data from industry. Ann Intern Med 119: 681687.
  • 8
    Guerciolini, R. (1997) Mode of action of orlistat. Int J Obes 21 (Suppl. 3): S1223.
  • 9
    Prentice, A. M., Jebb, S. A. (1995) Obesity in Britain: gluttony or sloth? BMJ 311: 437439.
  • 10
    Rolls, B., Shide, D. J. (1992) The influence of dietary fat on food intake and body weight. Nutr Rev 50: 283290.
  • 11
    Blundell, J. E., Lawton, C. L., Hill, AJ. (1993) Mechanisms of appetite control and their abnormalities in obese patients. Horm Res 39 (Suppl. 3): 726.
  • 12
    Hauptman, J. B., Jeunet, F. S., Hartmann, D. (1992) Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro18-0647 (tetrahydrolipstatin). Am J Clin Nutr 5: 309S313S.
  • 13
    Zhi, J., Melia, A. T., Guerciolini, R., Chung, J., Kingberg, J., Hauptman, J. R. (1994) Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 56: 8285.
  • 14
    Drent, M. L., van der Veen E. A. (1993) Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes 17: 241244.
  • 15
    Drent, M. L., Larsson, I., William-Olsson, T., et al (1995) Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 19: 221226.
  • 16
    Sjöström, L., Rissanen, A., Andersen, T., et al (1998) Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352: 167172.
  • 17
    van Gaal, L. F., Broom, J. I., Enzi, G., Toplak, H., Orlistat Dose Ranging Study Group (1998) Efficacy and tolerability of orlistat in the treatment of obesity: a 6 month dose ranging study. Eur J Clin Pharmacol. 54: 12532.
  • 18
    Mathias, S. D., Williamson, C. L., Colwell, H. H., et al (1997) Assessing health-related quality of life and health state preference in persons with obesity: a validation study. Qual Life Res 6: 311322.
  • 19
    Pfohl, M., Luft, D., Blomberg, I., Schmulling, R-M. (1994) Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. Int J Obes 18: 391395.
  • 20
    Thomas, P. R. (1995) Weighing the options. Criteria for evaluating weight management programs National Academy Press Institute of Medicine, Washington (DC).
  • 21
    Skender, M. L., Goodrick, G. K., Del Junco, D. J., et al (1996) Comparison of 2-year weight loss trends in behavioral treatments of obesity: diet, exercise, and combination interventions. J Am Diet Assoc 96: 342346.
  • 22
    Kramer, F. M., Jeffery, R. W., Forster, J. L., Snell, M. K. (1989) Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes 13: 123136.
  • 23
    Guy-Grand, B., Apfelbaum, M., Crepaldi, G., Gries, A., Lefebvre, P., Turner, P. (1989) International trial of long-term dexfenfluramine in obesity. Lancet ii: 11421145.
  • 24
    Ryan, D. H., Bray, G. A., Williamson, D. A., Champagne, CM. (1996) Treatment for 21/2 years with sibutramine. Obes Res 4 (Suppl. 1): AO73.
  • 25
    Tonstad, S., Pometta, D., Erkelens, D. W., et al (1994) The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 46: 405410.
  • 26
    Larsson, B. (1992) Obesity and body fat distribution as predictors of coronary heart disease. Marmot, M. Elliott, P. eds. Coronary Heart Disease Epidemiology. From Aetiology to Public Health Oxford University Press Oxford. 23341.
  • 27
    Lean, M. E., Han, T. S., Morrison, C. E. (1995) Waist circumference as a measure indicating need for weight management. BMJ 311: 11501162.
  • 28
    Han, T. S., van Leer, E. M., Seidell, J. C., Lean M. E. (1995) Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 311: 14011405.
  • 29
    Melia, A. T., Koss-Twardy, S. G., Zhi, J. (1996) The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 36: 647653.
  • 30
    Zhi, J., Melia, A. T., Koss-Twardy, S. G., Arora, S., Patel, I. H. (1996) The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 36: 152159.